Pipeline
Our pipeline reflects Endeavor’s commitment to advancing innovative therapies for fibrotic diseases with high unmet need. Guided by insights into fibrosis biology and informed by clinical proof of concept in idiopathic pulmonary fibrosis (IPF), we are developing programs designed to address the underlying mechanisms that drive disease progression.
Endeavor BioMedicines’ Pipeline
Taladegib
IPF
Hedgehog Pathway Inhibitor
Undisclosed Program
Hedgehog Pathway Inhibitor
Undisclosed Program
Hedgehog Pathway Inhibitor
Phase 2a Clinical Trial Results
Endeavor BioMedicines previously published results from a completed Phase 2a clinical trial that demonstrate our lead investigational candidate, taladegib (ENV-101), improved lung function, increased total lung capacity and reversed key measures of lung fibrosis in patients with idiopathic pulmonary fibrosis (IPF).
